Home › Major Depressive Disorder › Illinois › Naperville
Major Depressive Disorder clinical trials in Naperville, IL
4 studies for Major Depressive Disorder are looking for participants at sites in and around Naperville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RecruitingPhase 3
- Baber Research Group, Naperville
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
RecruitingPhase 2
- AMR Conventions Research, Warrenville · 3 mi away
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RecruitingPhase 4
- Neurocrine Clinical Site, Naperville
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RecruitingPhase 2
- Amr Conventions Research /ID# 277547, Warrenville · 3 mi away
Major Depressive Disorder trials in other cities
- New York City, NY34 studies
- Boston, MA31 studies
- Atlanta, GA24 studies
- Houston, TX21 studies
- Philadelphia, PA20 studies
- Orlando, FL18 studies
- Miami, FL17 studies
- Tampa, FL17 studies
- Chicago, IL15 studies
- San Diego, CA14 studies
- Orange, CA13 studies
- Las Vegas, NV13 studies
Other studies in Naperville
- Non-Small Cell Lung Cancer15 studies
- Lung Cancer13 studies
- Heart Failure11 studies
- Breast Cancer10 studies
- Prostate Cancer10 studies
- Cardiovascular Disease8 studies
- Pancreatic Cancer6 studies
- Macular Degeneration6 studies
- Geographic Atrophy6 studies
- Colon Cancer6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Atrial Fibrillation5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.